title: Predictors of death from chronic graft-versus-host disease after bone marrow transplantation.
abstract: Chronic graft-v-host disease (chronic GVHD) is a frequent cause of late morbidity and death after bone marrow transplantation (BMT). The actuarial survival after onset of chronic GVHD in 85 patients was 42% (95%Cl = 29%, 54%) at 10 years. Baseline characteristics present at the onset of chronic GVHD (before therapy) in 85 patients were reviewed to determine which were risk factors for death. In a multivariate proportional hazards analysis, three baseline factors emerged as independent predictors of death: progressive presentation (chronic GVHD following acute GVHD without resolution of acute GVHD; hazard ratio of 4.1, 95% Cl = 2.1 to 7.8), lichenoid changes on skin histology (hazard ratio of 2.2, 95% Cl = 1.1 to 4.3), and elevation of serum bilirubin greater than 1.2 mg/dL (hazard ratio = 2.1, 95% Cl = 1.1 to 4.1). Actuarial survival of 23 chronic GVHD patients with none of these risk factors was 70% at 6 years (95% Cl = 38%, 88%). Thirty-eight patients with one of these risk factors had a projected 6-year survival of 43% (95% Cl = 21%, 63%). The 29 patients with any combination of two or more of these factors had a projected 6-year survival of only 20% (95% Cl = 8%, 37%). Identification of baseline risk factors should facilitate design of trials of chronic GVHD therapies and assignment of high-risk patients to more aggressive innovative therapeutic regimens.
authors.affiliation: Oncology Center, Johns Hopkins Medical Institutions, Baltimore, MD 21205.
authors.forename: J R
authors.initials: JR
authors.lastname: Wingard
authors.forename: S
authors.initials: S
authors.lastname: Piantadosi
authors.forename: G B
authors.initials: GB
authors.lastname: Vogelsang
authors.forename: E R
authors.initials: ER
authors.lastname: Farmer
authors.forename: D A
authors.initials: DA
authors.lastname: Jabs
authors.forename: L S
authors.initials: LS
authors.lastname: Levin
authors.forename: W E
authors.initials: WE
authors.lastname: Beschorner
authors.forename: R A
authors.initials: RA
authors.lastname: Cahill
authors.forename: D F
authors.initials: DF
authors.lastname: Miller
authors.forename: D
authors.initials: D
authors.lastname: Harrison
mesh_terms: D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D001379:Azathioprine / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D005260:Female; D006086:Graft vs Host Disease / Q000401:mortality* / Q000517:prevention & control; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000401:mortality / Q000517:prevention & control; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis
chemical_list: D001379:Azathioprine; D011241:Prednisone